# PD-L1 Targeting Peptide Probe for PET Imaging of Solid Tumor

> **NCT07442292** · — · NOT_YET_RECRUITING · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 40 (estimated)

## Conditions studied

- Lung Cancer (NSCLC)
- Lung Cancer (SCLC)
- Melanoma (Skin Cancer)
- Melanoma Metastatic
- PD-L1
- PET / CT

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07442292
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02
- **Primary completion:** 2026-12
- **Final completion:** 2027-06
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07442292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07442292, "PD-L1 Targeting Peptide Probe for PET Imaging of Solid Tumor". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07442292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*